"Eicosapentaenoic Acid" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Important polyunsaturated fatty acid found in fish oils. It serves as the precursor for the prostaglandin-3 and thromboxane-3 families. A diet rich in eicosapentaenoic acid lowers serum lipid concentration, reduces incidence of cardiovascular disorders, prevents platelet aggregation, and inhibits arachidonic acid conversion into the thromboxane-2 and prostaglandin-2 families.
Descriptor ID |
D015118
|
MeSH Number(s) |
D10.212.302.380.410.385 D10.251.355.255.200 D10.251.355.337.290 D10.627.430.450.390
|
Concept/Terms |
Eicosapentaenoic Acid- Eicosapentaenoic Acid
- Eicosapentanoic Acid
- Acid, Eicosapentanoic
- omega-3-Eicosapentaenoic Acid
- omega 3 Eicosapentaenoic Acid
- Timnodonic Acid
- 5,8,11,14,17-Eicosapentaenoic Acid
- 5,8,11,14,17-Icosapentaenoic Acid
|
Below are MeSH descriptors whose meaning is more general than "Eicosapentaenoic Acid".
Below are MeSH descriptors whose meaning is more specific than "Eicosapentaenoic Acid".
This graph shows the total number of publications written about "Eicosapentaenoic Acid" by people in this website by year, and whether "Eicosapentaenoic Acid" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2002 | 0 | 1 | 1 |
2003 | 1 | 0 | 1 |
2004 | 2 | 1 | 3 |
2008 | 1 | 0 | 1 |
2010 | 3 | 0 | 3 |
2011 | 1 | 0 | 1 |
2012 | 3 | 0 | 3 |
2013 | 7 | 1 | 8 |
2014 | 2 | 1 | 3 |
2015 | 3 | 1 | 4 |
2016 | 4 | 0 | 4 |
2017 | 3 | 1 | 4 |
2018 | 4 | 0 | 4 |
2019 | 7 | 4 | 11 |
2020 | 5 | 3 | 8 |
2021 | 3 | 1 | 4 |
2022 | 2 | 5 | 7 |
2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Eicosapentaenoic Acid" by people in Profiles.
-
What is really new in triglyceride guidelines? Curr Opin Endocrinol Diabetes Obes. 2023 04 01; 30(2):73-80.
-
Effects of Randomized Treatment With Icosapent Ethyl and a Mineral Oil Comparator on Interleukin-1?, Interleukin-6, C-Reactive Protein, Oxidized Low-Density Lipoprotein Cholesterol, Homocysteine, Lipoprotein(a), and Lipoprotein-Associated Phospholipase A2: A REDUCE-IT Biomarker Substudy. Circulation. 2022 Aug 02; 146(5):372-379.
-
Prevention of Cardiovascular Events and Mortality With Icosapent Ethyl in Patients With Prior?Myocardial Infarction. J Am Coll Cardiol. 2022 05 03; 79(17):1660-1671.
-
Impact of Icosapent Ethyl on Cardiovascular Risk Reduction in Patients With Heart Failure in REDUCE-IT. J Am Heart Assoc. 2022 04 05; 11(7):e024999.
-
Treatment With Icosapent Ethyl to Reduce Ischemic Events in Patients With Prior Percutaneous Coronary Intervention: Insights From REDUCE-IT PCI. J Am Heart Assoc. 2022 03 15; 11(6):e022937.
-
A Head-to-Head Comparison of a Free Fatty Acid Formulation of Omega-3 Pentaenoic Acids Versus Icosapent Ethyl in Adults With Hypertriglyceridemia: The ENHANCE-IT Study. J Am Heart Assoc. 2022 03 15; 11(6):e024176.
-
Cost-effectiveness of Icosapent Ethyl for High-risk Patients With Hypertriglyceridemia Despite Statin Treatment. JAMA Netw Open. 2022 02 01; 5(2):e2148172.
-
Consistency of Benefit of Icosapent Ethyl by Background Statin Type in REDUCE-IT. J Am Coll Cardiol. 2022 01 18; 79(2):220-222.
-
Icosapent Ethyl Reduces Ischemic Events in Patients With a History of Previous Coronary Artery Bypass Grafting: REDUCE-IT CABG. Circulation. 2021 12 07; 144(23):1845-1855.
-
Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients With Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL. Circulation. 2021 11 30; 144(22):1750-1759.